Published in Proteomics Weekly, November 2nd, 1998
Genital herpes simplex virus (HSV) infection affects millions of people worldwide and causes significant morbidity, especially in sexually active young adults (Nahmias et al., Scand J Infect Dis Suppl, 1990;69:19-36; Johnson et al., N Engl J Med, 1989;321:7-12; and others).
M. Reitano, Reitano and Stern Research, New York, and colleagues performed a randomized, double-blind study of valaciclovir for the suppression of recurrent genital herpes among 1,479 immunocompetent patients ("Valaciclovir for the Suppression of Recurrent Genital...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly